leisure time -WSS

leisure time

author：knowledge 2025-09-28 12:08:42 - browse：77

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： How artificial intelligence is being used to detect, treat cancer

explore

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Caitlin Bernard's story shows physicians can't shy from advocacy

Roche drug slashes death risk in early

Study on Amgen’s bispecific immunotherapy produces positive data

focus

leisure time

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

FDA official pushes for dedicated emerging pathogens team

Walensky prepares to leave CDC — and Congress — behind

AbbVie dramatically boosts its spending on lobbying

Cancer drug shortages should be causing more outrage

As Taiwan prepares for anti

Medical leaders decry Supreme Court decision on affirmative action

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Duchenne breakthrough therapy leaves behind pioneering families

White House launches permanent pandemic office

focus

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

HIPAA doesn't protect reproductive records from prosecutors

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Providers still hesitate to prescribe buprenorphine, study finds

AbbVie dramatically boosts its spending on lobbying

Readout LOUD podcast: Live from the 2023 STAT Summit

explore

explore

hotspot

focus